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Pluripotent Stem Cells: The Search for the 
“Perfect” Source 
Nancy M.P. King*, Christine Nero Coughlin** & 
Anthony Atala*** 
Anyone who dreamed that the public controversy over 
human embryonic stem cell (hESC) research had begun to die 
down was rudely awakened by the decision in Sherley v. 
Sebelius.1 On August 23, District of Columbia District Court 
Judge Royce Lamberth issued a preliminary injunction halting 
federal funding of research using newly created hESC lines 
until the plaintiffs’ challenge to the 2009 liberalization of 
funding guidelines can be heard.2 On September 9, 2010, the 
Court of Appeals for the District of Columbia temporarily 
stayed Judge Lamberth’s order,3 and on September 28, 2010, 
the Court of Appeals ordered that the appeal be expedited and 
granted the Obama administration’s motion to permit federally 
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 1. Sherley v. Sebelius, 704 F. Supp. 2d 63 (D.D.C. 2010), appeal docketed, 
No. 10-5287 (D.C. Cir. Sept. 9, 2010) (order granting preliminary injunction). 
 2. Id. at 66. 
 3. Sherley v. Sebelius, No. 10-5287 (D.C. Cir. Sept. 9, 2010). 
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funded hESC research to go forward during the appeal.4 
This dispute over federal funding might seem relatively 
insignificant at first. Since the enactment of the Dickey-Wicker 
Amendment5 restricting the availability of funds for hESC 
research, many states have set aside funding for hESC 
research6—in some cases in significant amounts.7 Private 
funding is also available from the pharmaceutical industry and 
disease advocacy foundations.8 Investigators and academic 
medical centers have become accustomed to separating their 
cell lines, equipment, and activities so that there is no 
commingling of federally funded hESC research with hESC 
research that cannot receive federal support.9 And finally, 
there are many alternate sources of highly pluripotent stem 
cells, though the scientific and practical promise of these 
sources is, as we shall see, highly variable. 
Nonetheless, this renewed focus on the Dickey-Wicker 
Amendment demonstrates both the sensitivity of hESC 
research and the complexity of the science, ethics, and policy 
surrounding research using all forms of human stem cells. 
Even the most cursory examination of this wide-ranging area of 
scientific progress and policy discussion illustrates the futility 
of searching for the “perfect” stem cell source. 
I. A SHORT HISTORY 
The Dickey-Wicker Amendment was initially enacted in 
1996 as a rider to appropriations legislation passed by 
 4. Sherley v. Sebelius, No. 10-5287 (D.C. Cir. Sept. 28, 2010) (granting 
defendants’ motion to stay pending appeal and expediting appeal). 
 5. Balanced Budget Downpayment Act, Pub. L. No. 104–99, § 128, 110 
Stat. 26, 34 (1996). 
 6. See, e.g., CAL. CONST. art. XXXV (establishing the California Institute 
for Regenerative Medicine and the state constitutional right to conduct stem 
cell research); CONN. GEN. STAT. § 19a-32e (West Supp. 2010); MD. CODE ANN. 
ECON. DEV. § 10-434 (LexisNexis 2008). 
 7. California Stem Cell Research and Cures Bond Act, CAL. HEALTH & 
SAFETY CODE § 125291.30 (effective Nov. 3, 2004) (authorizing the issuance of 
three billion dollars in bonds for the purposes of conducting stem cell 
research). 
 8. See, e.g., Dena Davis & Debra Grega, Lines of Communication: 
Advances in Stem Cell Policy, 23 J. L. & HEALTH 29, 35 (2010). 
 9. National Institutes of Health Guidelines for Human Stem Cell 
Research, 74 Fed. Reg. 32,170, 32,171–73 (July 7, 2009), available at 
http://stemcells.nih.gov/policy/2009guidelines.htm.   
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Congress in 1995.10 It has been reenacted yearly since then. 
The amendment prohibits the Department of Health and 
Human Services from using appropriated funds for “(1) the 
creation of a human embryo or embryos for research purposes; 
or (2) research in which a human embryo or embryos are 
destroyed, discarded, or knowingly subjected to risk of injury or 
death greater than that allowed for research on fetusesin utero 
. . . .”11 The amendment defines a human embryo as any 
organism “derived by fertilization, parthenogenesis, cloning, or 
any other means from one or more human gametes.”12 
In 2001, President George W. Bush instituted a policy 
permitting limited federal funding for research using hESC 
lines that existed as of August ninth of that year.13 Later, he 
twice vetoed legislation to expand federal financing for hESC 
research,14 and issued an Executive Order calling for further 
research on alternative sources of pluripotent stem cells.15 
When Bush’s policy was instituted, the NIH estimated that 64 
lines were available for use.16 Late in his term, however, there 
were only about 20 embryonic stem cell lines approved for use 
in federally funded studies. Many of these lines were 
considered to be contaminated, to lack genetic diversity, or to 
be otherwise insufficient for medical research.17 Legislation to 
change the date by which hESC lines must have been created 
to be used in federally funded research repeatedly failed in 
Congress during the Bush Administration. 
 10. Balanced Budget Downpayment Act § 128. 
 11. Id. 
 12. Id. 
 13. Address to the Nation on Stem Cell Research, 2 PUB. PAPERS 953, 
955–56 (Aug. 9, 2001). 
 14. President’s Message to the Senate Returning Without Approval the 
“Stem Cell Research Enhancement Act of 2007,” 43 WEEKLY COMP. PRES. 
DOC. 833 (June 20, 2007); George W. Bush, President’s Message to the House 
of Representatives Returning Without Approval the “Stem Cell Research 
Enhancement Act of 2005,” 42 WEEKLY COMP. PRES. DOC. 1365 (July 19, 
2006). 
 15. Exec. Order No. 13,435, 72 Fed. Reg. 34,591 (June 20, 2007). 
 16. John A. Robertson, Embryo Stem Cell Research: Ten Years of 
Controversy, 38 J.L. MED. & ETHICS 191, 195 n.26 (2010). 
 17. E.g., Ruth R. Faden et al., Public Stem Cell Banks: Considerations of 
Justice in Stem Cell Research and Therapy, 33 HASTINGS CENTER REP. 13, 13–
27 (2003); Stephen S. Hall, Stem Cells: A Status Report, 36 HASTINGS CENTER 
REP. 16, 16–22 (2006); Annie D. Lyerly & Ruth R. Faden, Embryonic Stem 
Cells: Willingness to Donate Frozen Embryos for Stem Cell Research, 317 
SCIENCE 46, 46–47 (2007); Robertson, supra note 16, at 195 n.26. 
 718 MINN. J. L. SCI. & TECH. [Vol. 12:2 
 
                                                          
 
Thus, when President Obama issued a new Executive 
Order permitting federal funding of research using newly 
created cell lines from embryos originally created for in vitro 
fertilization and later donated for research,18 the change was 
viewed as a simple modification of the date by which approved 
stem cell lines could be created.19 The source of embryos was 
considered largely uncontroversial because the embryos were 
not created for research and would otherwise be discarded or 
stored indefinitely. Concerns remained that the number of 
embryos available for research as a result of in vitro 
fertilization might not make available a sufficient number of 
optimally robust cell lines.20 Still, it was not anticipated that 
the interpretation of the Dickey-Wicker amendment’s language 
would become a source of controversy. 
However the Sherley v. Sebelius litigation is ultimately 
resolved, it is clear that disagreement and concern about the 
status of embryos and divergent views among scientists21 and 
the public22 about morally appropriate sources of and uses for 
hESCs will persist.23 Although new sources of potentially 
useful stem cells are hinted at almost daily in both the 
scientific literature and the popular press,24 profound optimism 
about the therapeutic promise of hESCs coexists with 
uncertainty about when that promise will be realized, ensuring 
that scientists will continue their quest for better sources of 
pluripotent stem cells. 
 18. Exec. Order No. 13,505, 74 Fed. Reg. 10,667, 10,668 (Mar. 9, 2009). 
 19. See generally National Institutes of Health Guidelines for Human 
Stem Cell Research, supra note 9, at 32,173. 
 20. See Faden et al., supra note 17, at 13–27; Lyerly & Faden, supra note 
17, at 46–47. See also David I. Hoffman et al., Cryopreserved Embryos in the 
United States and Their Availability for Research, 79 FERTILITY & STERILITY 
1063, 1063–69 (2003). 
 21. See generally S.P. Wainwright, et al., Ethical Boundary-work in the 
Embryonic Stem Cell Laboratory, 28 SOC. HEALTH & ILLNESS 732, 744–45 
(2006). 
 22. Lyerly & Faden, supra note 17, at 46–47. 
 23. See generally CYNTHIA B. COHEN, RENEWING THE STUFF OF LIFE: 
STEM CELLS, ETHICS, AND PUBLIC POLICY (2007). 
 24. Macro Seandel et al., Generation of Functional Multipotent Adult 
Stem Cells from GPR1251 Germline Progenitors, 449 NATURE 346, 346–350 
(2007). 
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II. hESCS IN BRIEF 
In 1981, pluripotent cells were found in the inner cell mass 
of the mouse embryo, and the term “embryonic stem cell” was 
coined.25 The ability to retrieve human embryonic stem cells 
was described in 1998.26 These cells are able to differentiate 
into all cells of the human body, excluding placental cells (only 
cells from the morula are totipotent; that is, able to develop 
into all cells of the human body). Human embryonic stem cells 
are highly versatile, able to give rise to all types of cells and to 
be “immortalized,” or perpetually propagated in a cell line.27 
Their versatility makes them valuable for research and 
treatment. However, they also have the intrinsic property of 
forming teratoma tumors.28 
Ethical and policy arguments about the legal and moral 
status of the embryo and preembryo are so familiar to most of 
us that they no longer engage the intellect, but only serve to 
harden apparently irreconcilable viewpoints. Each new 
alternative source of highly multipotent stem cells seems to 
alter the balance of arguments only slightly, exchanging some 
concerns for others but never changing the moral landscape 
enough to change minds.29 
Opponents of hESC research posit that all human zygotes 
and embryos deserve significant protections because of their 
potential for human development, regardless of whether that 
potential will ever be realized.30 While each cell in a zygote, or 
very early embryo, is totipotent, that is, fully able to develop 
into a complete embryo, the cells and cell lines derived from 
human embryos are instead pluripotent: highly versatile but 
not able to become new embryos. For this reason, contemporary 
 25. Gail R. Martin, Isolation of a Pluripotent Cell Line from Early Mouse 
Embryos Cultured in Medium Conditioned by Teratocarcinoma Stem Cells, 78 
PROC. NAT’L ACAD. SCI. U.S. 7634, 7635–38 (1981). 
 26. James A. Thomson et al., Embryonic Stem Cell Lines Derived from 
Human Blastocysts, 282 SCIENCE 1145, 1145–46 (1998). 
 27. Junying Yu & James A. Thomson, Embryonic Stem Cells, as reprinted 
in NAT’L INSTS. OF HEALTH, REGENERATIVE MEDICINE 1 (2006), 
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/Regenerative_Medi
cine_2006.pdf. 
 28. Davor Solter, From Teratocarcinomas to Embryonic Stem Cells and 
Beyond: A History of Embryonic Stem Cell Research, 7 NATURE REV. GENETICS 
319, 319–20 (2006). 
 29. See generally COHEN, supra note 23. 
 30. Russell Korobkin, Stem Cell Research and the Cloning Wars, 18 STAN. 
L. & POL’Y REV. 161, 171 (2007). 
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arguments in opposition to hESC research focus on the 
destruction of embryos capable of developing into adult 
humans, rather than on the moral status of the hESCs 
themselves.31 
In contrast, proponents of hESC research employ a range 
of deontological and consequentialist arguments, from the 
proposition that human embryos should be viewed as biological 
property, afforded no special protection, to holding that human 
embryos should be afforded an intermediate moral status with 
some special protections, but not a status equivalent to that of 
a living infant or adult human.32 Terms like ‘spare,’ ‘extra,’ 
‘leftover,’ ‘discarded,’ ‘abandoned,’ and ‘unwanted’ are used to 
characterize human embryos created for assisted reproduction 
but frozen and unused. A utilitarian calculus is often employed 
to justify using these embryos—the most commonly discussed 
potential source of new hESC lines, and the source referenced 
in President Obama’s Executive Order and the revised 2009 
Guidelines—in research. Many couples who have attempted in 
vitro fertilization have expressed willingness to donate frozen 
embryos for this purpose.33 
III. ALTERNATIVE SOURCES 
Sherley v. Sebelius has now redoubled attention to deriving 
highly pluripotent stem cell lines in ways that do not destroy 
human embryos. These methods can be organized into several 
categories: (1) somatic cell reprogramming; (2) other non-
embryonic sources; (3) employing artificial and asexual 
methods to create embryos; and (4) extracting hESCs from 
embryos without embryo destruction. Each method shows 
considerable promise, and each raises scientific, ethical, and 
policy questions of its own. 
A. SOMATIC CELL REPROGRAMMING: INDUCED PLURIPOTENT 
STEM CELLS 
The newest and, to many, the most exciting alternative to 
hESC research is the development of pluripotent cells through 
somatic stem cell reprogramming. In this process, either 
 31. See generally COHEN, supra note 23. 
 32. John A. Robertson, Ethics and Policy in Embryonic Stem Cell 
Research, 9 KENNEDY INST. ETHICS J. 109, 110–130 (June 1999). 
 33. Lyerly & Faden, supra note 17, at 46–47. 
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somatic cells or determined stem cells are stimulated by the 
introduction of genetic material to evolve backward to a state of 
pluripotency. The resulting induced pluripotent stem cells 
(iPSCs) can then be grown into cell lines.34 This process mimics 
the limb regeneration capacities of some amphibians.35 The 
most significant moral concern that has been raised about this 
research is that the process could be pursued beyond 
pluripotency to totipotency. This concern appears, however, to 
be entirely speculative. 
First created in 2007,36 iPSCs hold great promise as an 
alternative to hESCs. To create them, pluripotency is induced 
in a somatic cell (or sometimes in a so-called “adult stem cell,” 
which can generate a single cell type) by genetically 
reprogramming it to dedifferentiate into a pluripotent state. In 
a clinical setting, this method could facilitate the growth of 
compatible cells, tissues, or organs from a patient’s own cells.37 
In a research setting, iPSC lines could facilitate the close study 
of many genetic disorders and the genetic contributions to 
common complex disorders. This technique thus has potential 
uses very similar to those of somatic cell nuclear transfer, 
without the need for oocytes.38 
Several scientific obstacles must be overcome, however, 
before iPSCs can be demonstrated to be as useful as hESCs. 
Safety is a key consideration in the process of generating 
 34. NAT’L RES. COUNCIL & INST. OF MED., FINAL REPORT OF THE 
NATIONAL ACADEMIES’ HUMAN EMBRYONIC STEM CELL RESEARCH ADVISORY 
COMMITTEE AND 2010 AMENDMENTS TO THE NATIONAL ACADEMIES’ 
GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH App’x C (2010) 
[hereinafter GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH], 
available at http://www.nap.edu/catalog.php?record_id=12923; Chad A. Cowan 
et al., Nuclear Reprogramming of Somatic Cells After Fusion with Human 
Embryonic Stem Cells, 309 SCIENCE 1369 (2005); Keisuke Okita et al., 
Generation of Germline-Competent Induced Pluripotent Stem Cells, 448 
NATURE 313, 313–14 (2007); Marius Wernig et al., In Vitro Reprogramming of 
Fibroblasts into a Pluripotent ES-Cell-Like State, 448 NATURE 318, 321–22 
(2007). 
 35. Panagiotis A. Tsonis, Bridging Knowledge Gaps on the Long Road to 
Regeneration: Classical Models Meet Stem Cell Manipulation and 
Bioengineering, 7 MOLECULAR INTERVENTIONS 249, 249 (2007). 
 36. Yoshinori Yoshida & Shinya Yamanaka, Recent Stem Cell Advances: 
Induced Pluripotent Stem Cells for Disease Modeling and Stem Cell-Based 
Regeneration, 122 CIRCULATION 80, 80 (2010). 
 37. George Q. Daley, Stem Cells: Roadmap to the Clinic, 120 J. CLINICAL 
INVESTIGATION 8, 9 (2010); Christopher J. Lengner, iPS Cell Technology in 
Regenerative Medicine, 1192 ANNALS N.Y. ACAD. SCI. 38, 39–40 (2010). 
 38. See infra Part III.C.1. 
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iPSCs. Most current methods of iPSC creation require the 
introduction of genetic material into the cell. This is often 
achieved by using viral vectors, as in gene transfer research, 
and thus introduces comparable risks, including the possibility 
of inducing cancers through insertional mutagenesis.39 Uses of 
non-integrating vectors or removable viral vectors, non-viral 
vectors, and non-genetic means of reprogramming cells to a 
pluripotent state are in development in many laboratories.40 In 
a recent development, the use of non-integrating synthetic 
messenger RNA for cell reprogramming appears potentially 
safe and efficient.41 The intrinsic propensity of iPSCs, like 
hESCs, to form teratoma tumors, however, may still pose a 
risk.42 Some recent experiments show potential for 
circumventing these issues, but any risk of tumorigenicity 
remains a challenge.43 
Finally, because decades of research have established 
hESCs as the researcher’s gold standard, even as iPSCs are 
increasingly studied, hESCs will continue to be necessary in 
research, particularly as controls. Accordingly, the ethical 
concerns attending the use of hESCs are likely to accompany 
much iPSC research for the time being. Many uncertainties 
about the safety, effectiveness and cost of iPSC development 
and use in research are yet to be determined. 
 39. See Salima Hacein-Bey-Abina et al., A Serious Adverse Event After 
Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency, 
348 NEW ENG. J. MED. 255, 255 (2003). 
 40. See Rudolf Jaenisch & Richard Young, Stem Cells, the Molecular 
Circuitry of Pluripotency and Nuclear Reprogramming, 132 CELL 567, 576 
(2008); Lengner, supra note 37, at 40; Wenlin Li et al., Generation of Rat and 
Human Induced Pluripotent Stem Cells by Combining Genetic Reprogramming 
and Chemical Inhibitors, 4 CELL STEM CELL 16, 18–19 (2009); Keisuke Okita 
et al., Generation of Mouse Induced Pluripotent Stem Cells Without Viral 
Vectors, 322 SCIENCE 949, 949–52 (2008); Takashi Tada, Genetic Modification-
Free Reprogramming to Induced Pluripotent Cells: Fantasy or Reality?, 3 CELL 
STEM CELL 121–22 (2008). 
 41. Luigi Warren et al., Highly Efficient Reprogramming to Pluripotency 
and Directed Differentiation of Human Cells with Synthetic Modified mRNA, 7 
CELL STEM CELL 1, 6–7 (2010). 
 42. See Andrew Pollack, Stem Cell Trial Wins Approval of F.D.A., N.Y. 
TIMES, July 31, 2010, at B1. 
 43. See Lengner, supra note 37, at 39. 
 2011] PLURIPOTENT STEM CELLS 723 
                                                          
B. NON-EMBRYONIC SOURCES: AMNIOTIC FLUID AND 
PLACENTAL CHORIONIC VILLI 
Scientists have also discovered that broadly multipotent 
stem cells capable of extensive expansion in laboratory culture 
have been isolated from what are often considered biological 
waste products: amniotic fluid and placental chorionic villi,44 
and the stromal tissue of umbilical cord.45 The discovery that 
amniotic fluid and placental tissue yields stem cells that are 
neither derived from nor capable of developing into a human 
embryo, yet are far more malleable and versatile than 
determined stem cells,46 is an exciting research prospect. The 
derivation of useful cell lines from non-embryonic sources does 
not, however, eliminate all ethical issues attendant upon this 
research. For example, concern exists that the desire to capture 
and store amniotic fluid stem cells will result in an increase in 
amniocentesis, which carries small but well-recognized risks of 
morbidity.47 However, similar cells can be obtained from the 
placenta, which is more readily accessible after birth and is 
also usually discarded.48 
The discovery of new sources of highly multipotent cells in 
potentially abundant biological waste materials like amniotic 
fluid and placenta presents the real possibility of creating 
publicly accessible stem cell banks which, by virtue of their size 
and completeness, could quickly amass stem cells in sufficient 
number and diversity to provide very good (albeit not perfect) 
matches for almost all of the human population.49 Building on 
the arguments for pooling and sharing stored umbilical cord 
blood, the creation of a cord blood and amniotic fluid stem cell 
bank would have great promise for research and, eventually, 
 44. M. Minhaj Siddiqui & Anthony Atala, Amniotic Fluid-Derived 
Pluripotential Cells, in 2 HANDBOOK OF STEM CELLS 175, 178–79 (Robert 
Lanza et al. eds., 2004); Ming-Song Tsai et al., Clonal Amniotic-Fluid Derived 
Stem Cells Express Characteristics of Both Mesenchymal and Neural Stem 
Cells, 74 BIOLOGY REPROD. 545, 550 (2006). 
 45. Alp Can & Sercin Karahuseyinoglu, Concise Review: Human 
Umbilical Cord Stroma with Regard to the Source of Fetus-Derived Stem Cells, 
25 STEM CELLS 2886, 2886–88 (2007). 
 46. Paolo De Coppi et al., Isolation of Amniotic Stem Cell Lines with 
Potential for Therapy, 25 NATURE BIOTECH. 100, 100–06 (2007). 
 47. See, e.g., John W. Seeds, Diagnostic Mid Trimester Amniocentesis: 
How Safe? 191 AM. J. OBSTET. GYNECOL. 608, 608-616 (2004). 
 48. De Coppi et al., supra note 46. 
 49. Faden et al., supra note 17, at 13. 
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for treatment, without traditional ethical concerns.50 
Traditional objections, however, may simply be replaced by 
concerns about stem cell banking, including questions about 
collection protocols, consent for collection, and the development, 
maintenance, and sharing of banked cells. Much work is 
needed to ensure the appropriate establishment and operation 
of amniotic fluid and placental stem cell banks. Systems for the 
collection, storage, and use of stem cells of different types are 
still in the early stages, both technologically and from a policy 
standpoint. Scientific, practical, and ethical issues raised 
include ensuring the broad availability of matches for those in 
need, determining access for research and for therapeutic uses, 
refining consent forms, information, and procedures, and 
developing robust systems for confidentially labeling 
biospecimens and linking them to the information needed for 
research and treatment. These issues have been well-rehearsed 
in cord blood banking but have not been solved or settled.51 
Future extensions to highly multipotent stem cells from 
amniotic fluid and placenta may be easier in some respects—for 
instance, the cells can be perpetuated and thus will not be used 
up when samples are taken for a particular use. Other issues 
may be more difficult. For example, the processing cost for 
amniotic fluid stem cells may be nontrivial. In addition, since 
amniotic fluid stem cells are expected to have a broader range 
of potential uses, the desired scope of consent could be 
controversially broad. 
C. ASEXUAL METHODS USING OOCYTES: SOMATIC CELL 
NUCLEAR TRANSFER, ALTERED NUCLEAR TRANSFER, AND 
PARTHENOGENESIS 
1. Somatic Cell Nuclear Transfer 
Artificial and asexual methods of stimulating the human 
oocyte to act like an embryo are yielding promising results. For 
 50. National Amniotic and Placental Stem Cell Bank Act of 2007, H.R. 
1892, 110th Cong. (as introduced by Rep. Lipinski, McIntyre, Shuler, 
Ellsworth, Melancon, and Donnelly on April 17, 2007); HOPE Act, S. 30, 110th 
Cong. (as passed by Senate on April 11, 2007); Amniotic Fluid and Placental 
Stem Cell Banking Act of 2007, S. 957, 110th Cong. (as introduced by Sen. 
Burr and Coleman on March 22, 2007)/ 
 51. E.g., Jeremy Sugarman et al., Ethical Issues in Umbilical Cord Blood 
Banking, 278 J. AM. MED. ASS’N 938 (1997). 
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example, in somatic cell nuclear transfer (SCNT), the nucleus 
of an oocyte is removed, replaced with a cell from another 
donor, and stimulated to engage in cell differentiation.52 After 
sufficient cell division, stem cells are extracted that are a 
genetic match to the donor, thus making this process, like iPSC 
creation, useful to study certain genetic diseases or to grow 
tissues and organs that will not be rejected.53 Concerns about 
the use of SCNT include the need to use large numbers of 
oocytes in order to produce a viable and stable stem cell line,54 
along with the issues of understanding, consent, and 
voluntariness that accompany oocyte procurement.55 This 
method, moreover, uses the same principles as reproductive 
cloning, giving rise to a slippery slope problem for some 
opponents.56 The possibility of using non-human oocytes could 
resolve concerns about oocyte procurement, but raises other 
questions of feasibility and the ethics of this type of chimera 
creation.57 
2. Altered Nuclear Transfer 
Scientists are therefore looking for ways to make 
reproduction impossible from cloned embryos. With this 
technology, called altered nuclear transfer (ANT), a gene that 
helps with implantation is deactivated during the growth of the 
blastocyst, but reactivated after harvesting stem cells in order 
 52. PRESIDENT’S COUNCIL ON BIOETHICS, MONITORING STEM CELL 
RESEARCH 111–12 (2004), available at 
http://bioethics.georgetown.edu/pcbe/reports/stemcell/pcbe_final_version_moni
toring_stem_cell_research.pdf. 
 53. Darwin J. Prockop, Embryonic Stem Cells Versus Adult Stem Cells: 
Some Seemingly Simple Questions, in ESSENTIALS OF STEM CELL BIOLOGY 
xxiii–xxiv (Robert Lanza et al. eds., 2006); Robert P. Lanza et al., Generation 
of Histocompatible Tissues Using Nuclear Transplantation, 20 NATURE 
BIOTECH. 689, 689–90 (2002). 
 54. David Magnus & Mildred K. Cho, Issues in Oocyte Donation for Stem 
Cell Research, 308 SCIENCE 1747, 1747 (2005); Narumi Ogonuki et al., Early 
Death of Mice Cloned from Somatic Cells, 30 NATURE GENETICS 253, 253 
(2002). 
 55. Josephine Johnston, Paying Egg Donors: Exploring the Arguments, 36 
HASTINGS CENTER REP. 28, 28–31 (2006); John A. Robertson, Technology and 
Motherhood: Legal and Ethical Issues in Human Egg Donation, 39 CASE W. 
RES. L. REV. 1, 31 (1989); Debora Spar, The Egg Trade: Making Sense of the 
Market for Human Oocytes. 365 NEW ENG. J. MED. 1289, 1289–90 (2007). 
 56. Korobkin, supra note 30, at 171. 
 57. See Stephen Minger, Interspecies SCNT-Derived Human Embryos—A 
New Way Forward for Regenerative Medicine, 2 REGENERATIVE MED. 103, 
103–05 (2007). 
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to create normal stem cell lines.58 ANT is a variation of SCNT 
in which a genetically modified nucleus from a somatic cell is 
transferred into a human oocyte. This embryo, which contains a 
deliberate genetic defect, is capable of developing into a 
blastocyst, but the induced defect prevents the blastocyst from 
implanting in the uterus. This process has the potential to 
generate customized hESCs from the blastocyst stage.59 
Human embryos with this genetic defect might lack the 
capacity to develop into viable fetuses, as a result of their 
inability to implant, thus providing a source of stem cells 
without destroying viable embryos. Proof of concept was 
obtained in mice by Meissner and Jaenisch using embryos 
lacking the Cdx2 homeobox gene.60 
The viability of human embryos lacking the Cdx2 gene is 
unclear, as is whether this mutation restricts human 
developmental potential into certain lineages. While much 
research must be done before therapeutic strategies based on 
this technique could ever enter the clinic, at this time hESCs 
derived from ANT can provide opportunities to study 
pluripotency in hESCs, without the need for destruction of 
viable embryos. The exact effects of Cdx2 gene knockout on the 
development of human embryos are not well known. Opponents 
contend, however, that using ANT does not overcome moral 
objections to this methodology.61 
3. Parthenogenesis 
Another method that focuses on oocyte stimulation and 
development is parthenogenesis, or “virgin birth.”62 This is the 
reproduction method of certain amphibians, and has been used 
to induce pregnancy artificially in mice. Here, an oocyte is 
chemically stimulated to undergo several rounds of cell 
division, as if it had been fertilized. The oocyte retains all 46 
 58. Alexander Meissner & Rudolf Jaenisch, Generation of Nuclear 
Transfer-Derived Pluripotent ES Cells from Cloned Cdx2-Deficient Blastocysts, 
439 NATURE 212, 214 (2006). 
 59. WB Hurlbut, Altered Nuclear Transfer as a Morally Acceptable Means 
for the Procurement of Human Embryonic Stem Cells, 48 PERSP. BIOLOGY & 
MED. 211, 222–26 (2005). 
 60. See Meissner & Jaenisch, supra note 58, at 212–14. 
 61. Hall, supra note 17, at 16–22; Korobkin, supra note 30, at 161, 171. 
 62. Kent Vrana et al., Nonhuman Primate Parthenogenetic Stem Cells, 
100 PROC. NAT’L ACAD. SCI. U.S. 11911, 11911, 11916 (2003). 
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chromosomes, and appears to lack developmental capacity 
beyond the blastocyst stage.63 It is uncertain whether a line 
obtained by this means would be stable or whether issues 
related to its parthenogenetic origin may limit its usefulness.64 
Moreover, the Dickey-Wicker Amendment includes research on 
human parthenogenesis in its list of federal funding 
prohibitions.65 
 
D. HESC WITHOUT EMBRYO DESTRUCTION: EXTRACTION AND 
“DEAD” EMBRYOS 
1. Extraction 
Using blastomere extraction, it may be possible to extract a 
single cell from embryos created for purposes of IVF, as is done 
for preimplantation genetic diagnosis (PGD).66 In 2006, Chung 
et al.67 were the first authors to report the generation of mouse 
embryonic stem cell lines in this manner. Cells were taken 
from eight-cell blastomeres rather than from blastocysts. The 
remaining four to six cells continue to divide and multiply as 
normal.68 The cells differentiated into derivatives of all three 
embryonic germ layers in vitro, as well as into teratomas in 
vivo. In addition, the mouse embryos that resulted from the 
biopsied blastomeres developed to term without a reduction in 
their developmental potential. In PGD, the removed cells are 
biopsied so that genetic testing can be performed. With 
blastomere extraction, the removed cells are cultured on feeder 
cells, from which stem cells can be derived.69 
Preimplantation genetic diagnosis now commonly 
accompanies IVF, particularly when there is concern about 
 63. Id. at 11912. See generally GUIDELINES FOR HUMAN EMBRYONIC STEM 
CELL RESEARCH, supra note 34. 
 64. Meissner & Jaenisch, supra note 53, at 213–14. 
 65. See Omnibus Appropriations Act, 2009, Pub. L. No. 111-8, § 509, 123 
Stat. 524, 803 (2009); see supra notes 10–12 and accompanying text. 
 66. Irina Klimanskaya et al., Human Embryonic Stem Cell Lines Derived 
from Single Blastomeres, 444 NATURE 481, 481–83 (2006). 
 67. Young Chung et al., Embryonic and Extraembryonic Stem Cell Lines 
Derived from Single Mouse Blastomeres, 439 NATURE 216, 219 (2006). 
 68. Irina Klimanskaya et al., Derive and Conquer: Sourcing and 
Differentiating Stem Cells for Therapeutic Applications, 7 NATURE REV. DRUG 
DISCOVERY 131, 132–35 (2008). 
 69. See Young Chung et al., Human Embryonic Stem Cell Lines Generated 
Without Embryo Destruction, 2 CELL STEM CELL 113, 113 (2008). 
 728 MINN. J. L. SCI. & TECH. [Vol. 12:2 
 
                                                          
 
inheritable disease. While some have raised concerns that the 
removal of a single cell from the developing embryo for PGD 
could pose significant risks to its development, so far it appears 
not to have adverse effects on embryos that are later implanted 
and progress to live birth.70 Moreover, if it is clearly shown to 
be safe to remove more than one cell from an embryo, in order 
to use one for PGD and one for development of a stem cell 
line—or, more probably, if it is reasonable to remove one cell, 
grow it overnight into a blastocyst, and use one of those cells 
for PGD and the rest for cell line development—then embryos 
need not be destroyed to pursue hESC research. This source of 
pluripotent stem cells, however, may require development to 
the blastocyst stage. If blastocysts are thought to deserve 
protection as future persons, then this source may be 
unacceptable to hESC research opponents. 
2. Dead Embryos 
Another possible way to obtain pluripotent stem cells 
without intentionally destroying the embryo would be to use 
only those spare IVF embryos that, after achieving the four-to-
eight cell division, undergo “cleavage arrest” or death.71 During 
IVF, only a small proportion of zygotes produced will develop 
successfully to the morula and blastocyst stages. Over half the 
embryos stop dividing, and are therefore considered dead 
embryos.72 Such embryos have unequal or fragmented cells and 
blastomeres and are usually discarded. While some of these 
embryos show chromosomal anomalies, others appear to be 
normally developed embryos from which stem cells can be 
extracted. Some researchers claim that there are reliable 
methods for determining whether or not the embryo has a 
normal chromosome complement, while others are skeptical 
about the viability of hESC lines derived from such embryos.73 
Advocates note that hESC lines derived from this method may 
have broad therapeutic application for genetic conditions. Some 
opponents of this method raise informed consent issues, as well 
 70. See Klimanskaya et al., supra note 66, at 481–84. 
 71. Donald W. Landry & Howard A. Zucker, Embryonic Death and the 
Creation of Human Embryonic Stem Cells, 114 J. CLINICAL INVESTIGATION 
1184, 1185 (2004). 
 72. Id. 
 73. Xin Zhang et al., Derivation of Human Embryonic Stem Cells from 
Developing and Arrested Embryos, 24 STEM CELLS 2669, 2670 (2006). 
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as ethical concerns over whether and when death actually 
occurs in embryos. 
IV. FUTURE PERFECT? 
Those who follow the stem cell debate are familiar with its 
rhythm: rapid proliferation of press information about possible 
new sources of pluripotent stem cells, followed by reflexive 
moral pronouncements, followed by questions about the 
science, followed by clarifications, qualifications, and additional 
expert views, followed by policy discussions (“Maybe we don’t 
need new legislation now after all . . .”), followed by the next 
round of new science. Unfortunately, the only dance that seems 
to fit this rhythm is “one step forward, two steps back.” We are 
not the first to argue that progress can only be made if all 
reasonable lines of research are pursued as science develops.74 
Waiting for the perfect source serves simply to make the best 
the enemy of the good. 
But there are other reasons not to await the perfect source. 
Here is one reason that is not usually offered: as we have seen 
even in this brief review, a prime requirement for a “perfect” 
source of pluripotent stem cells is that it have no “ethical 
baggage.”75 Physicians and scientists facing ethical issues 
arising in biomedicine and research often reason that if they 
wait for certainty—more facts, more information, more data—
the ethical issues will go away, having been answered by the 
science. 
They don’t. They never do. Science itself has values, as do 
scientists. Ethics and science are always intertwined. Waiting 
for perfection is a moral choice, and should be acknowledged as 
such. What it means for a source of pluripotent stem cells to be 
“free of ethical baggage” should be a subject of discussion. Since 
all ethical issues can never disappear from scientific and 
medical research, public discourse must continue as science 
advances. 
Research using pluripotent stem cells unquestionably 
strives to alleviate significant disease burdens, and the search 
 74. This scientific truism has been invoked many times. With respect to 
stem cells, see, for example, Jennifer Hipp & Anthony Atala, Sources of Stem 
Cells for Regenerative Medicine, 4 STEM CELL REVS. & REP. 3, 9 (2008); 
Zachary J. Kastenberg & Jon S. Odorico, Alternative Sources of Pluripotency: 
Science, Ethics, and Stem Cells, 22 TRANSPLANTATION REVS 215, 221 (2008). 
 75. Constance Holden, Versatile Stem Cells without the Ethical Baggage?, 
315 SCIENCE 170, 170–71 (2007). 
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for pluripotent stem cell-based therapies continues to show 
great promise, but the realization of effective therapies is still 
far in the future; thus, it is important not to overestimate the 
potential for benefit at this stage. As is the case for many new 
biotechnologies, however, the development of pluripotent stem 
cell science seeks a careful balance of scientific altruism and 
commercial interests. It is worth noting that underlying the 
arguments on all sides of the stem cell debate is some degree of 
concern about the potential for commodification, either of the 
person resulting from biotechnological advances or of the 
human biological products that permit desired designs to be 
realized. Only by acknowledging, critically examining, and 
discussing the concerns that may arise from pluripotent stem 
cell research can we hope to minimize its ethical and social 
risks. Ultimately, science and society must face the ethical 
issues openly, in order to move forward while searching for ever 
more perfect sources. 
 
